Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company's Expanding Global Leadership In The Development Of Innovative Antibody-Drug Conjugates

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 18 abstracts including eight oral presentations have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, Calif. from December 3-6, 2016. Collectively, the abstracts highlight advancement of the ADCETRIS (brentuximab vedotin) and vadastuximab talirine (SGN-CD33A) development programs and the company's expanding global leadership in antibody-drug conjugates (ADCs), as well as its commitment to developing investigational compounds that have the potential to improve therapeutic options for patients with blood-related cancers.

Data accepted for presentation at this year's ASH Annual Meeting include the following:
  • An oral presentation of full results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL)
  • Numerous oral and poster presentations highlighting additional progress within the ADCETRIS development program including:
    • Preliminary results from a phase 1/2 study of ADCETRIS in combination with Opdivo (nivolumab) among patients with relapsed or refractory Hodgkin lymphoma (HL)
    • Long-term (e.g., four-year) survival and durability results in patients with CD30-expressing peripheral T-cell lymphomas who received ADCETRIS with cyclophosphamide, hydroxydaunorubicin, and prednisone (CHP) as frontline therapy
    • Final five-year survival and durability results in relapsed systemic anaplastic large cell lymphoma (sALCL) patients who received ADCETRIS monotherapy
  • Four oral presentations featuring data from clinical studies exploring vadastuximab talirine in acute myeloid leukemia (AML), including newly diagnosed patients

"At this year's ASH Annual Meeting, we will present data from 18 abstracts, highlighting ADCETRIS, vadastuximab talirine and multiple pipeline programs," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. "The oral presentation of the complete results of the ALCANZA trial represents the fourth consecutive registrational trial for ADCETRIS with a positive outcome. Data across our pipeline programs continue to support the potential for antibody-drug conjugates to improve outcomes for patients with cancer."

If you liked this article you might like

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Biotech Movers: Clovis, Seattle Genetics, Rigel

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More